Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Signum’s phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. Signum has established a robust IP portfolio in the area of Signal Transduction Modulators (STMs). Signal transduction networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Signum has identified agents that perturb the two most central of these global regulatory mechanisms: G-Protein-Mediated membrane receptor signaling and Protein phosphorylation. G-Protein modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct stressful imbalances that can be detrimental to health and well-being.